Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Date publication

avril 2018

Journal

JAMA oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis , Pr DECONINCK Eric

Tous les auteurs :
Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29392283

Résumé

Pathogen reduction of platelet concentrates may reduce transfusion-transmitted infections but is associated with qualitative impairment, which could have clinical significance with regard to platelet hemostatic capacity.

Référence

JAMA Oncol. 2018 Apr 1;4(4):468-475